Cargando…

Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels

COVID-19 is characterized by persistent symptoms beyond acute illness. In this prospective cohort study of patients with COVID-19, we sought to characterize the prevalence and persistence of symptoms up to 18 months after diagnosis. We followed 166 patients and assessed their symptoms during acute i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalak, George, Jarjou’i, Amir, Bohadana, Abraham, Wild, Pascal, Rokach, Ariel, Amiad, Noa, Abdelrahman, Nader, Arish, Nissim, Chen-Shuali, Chen, Izbicki, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784691/
https://www.ncbi.nlm.nih.gov/pubmed/36556030
http://dx.doi.org/10.3390/jcm11247413
_version_ 1784857869514964992
author Kalak, George
Jarjou’i, Amir
Bohadana, Abraham
Wild, Pascal
Rokach, Ariel
Amiad, Noa
Abdelrahman, Nader
Arish, Nissim
Chen-Shuali, Chen
Izbicki, Gabriel
author_facet Kalak, George
Jarjou’i, Amir
Bohadana, Abraham
Wild, Pascal
Rokach, Ariel
Amiad, Noa
Abdelrahman, Nader
Arish, Nissim
Chen-Shuali, Chen
Izbicki, Gabriel
author_sort Kalak, George
collection PubMed
description COVID-19 is characterized by persistent symptoms beyond acute illness. In this prospective cohort study of patients with COVID-19, we sought to characterize the prevalence and persistence of symptoms up to 18 months after diagnosis. We followed 166 patients and assessed their symptoms during acute illness, and at 3 and 18 months after disease onset. The mean number of symptoms per patient during acute disease was 2.3 (SD:1.2), dropping to 1.8 (SD:1.1) at 3 months after recovery and to 0.6 (SD:0.9) at 18 months after recovery. However, this decrease was not unidirectional. Between acute illness and 3 months, the frequency of symptoms decreased for cough (64.5%→24.7%), ageusia (21.7% to6%), anosmia (17.5%→5.4%), and generalized pain (10.8% to 5.4%) but increased for dyspnea (53%→57.2%) weakness (47%→54.8%), and brain fog (3%→8.4%). Between 3 and 18 months, the frequency of symptoms decreased for all symptoms but remained relatively high for dyspnea (15.8%), weakness (21.2%), and brain fog (7.3%). Symptoms may persist for at least 18 months after acute COVID-19 infection. During the medium- to long-term recovery period, the prevalence of some symptoms may decrease or remain stable, and the prevalence of others may increase before slowly decreasing thereafter. These data should be considered when planning post-acute care for these patients.
format Online
Article
Text
id pubmed-9784691
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97846912022-12-24 Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels Kalak, George Jarjou’i, Amir Bohadana, Abraham Wild, Pascal Rokach, Ariel Amiad, Noa Abdelrahman, Nader Arish, Nissim Chen-Shuali, Chen Izbicki, Gabriel J Clin Med Article COVID-19 is characterized by persistent symptoms beyond acute illness. In this prospective cohort study of patients with COVID-19, we sought to characterize the prevalence and persistence of symptoms up to 18 months after diagnosis. We followed 166 patients and assessed their symptoms during acute illness, and at 3 and 18 months after disease onset. The mean number of symptoms per patient during acute disease was 2.3 (SD:1.2), dropping to 1.8 (SD:1.1) at 3 months after recovery and to 0.6 (SD:0.9) at 18 months after recovery. However, this decrease was not unidirectional. Between acute illness and 3 months, the frequency of symptoms decreased for cough (64.5%→24.7%), ageusia (21.7% to6%), anosmia (17.5%→5.4%), and generalized pain (10.8% to 5.4%) but increased for dyspnea (53%→57.2%) weakness (47%→54.8%), and brain fog (3%→8.4%). Between 3 and 18 months, the frequency of symptoms decreased for all symptoms but remained relatively high for dyspnea (15.8%), weakness (21.2%), and brain fog (7.3%). Symptoms may persist for at least 18 months after acute COVID-19 infection. During the medium- to long-term recovery period, the prevalence of some symptoms may decrease or remain stable, and the prevalence of others may increase before slowly decreasing thereafter. These data should be considered when planning post-acute care for these patients. MDPI 2022-12-14 /pmc/articles/PMC9784691/ /pubmed/36556030 http://dx.doi.org/10.3390/jcm11247413 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kalak, George
Jarjou’i, Amir
Bohadana, Abraham
Wild, Pascal
Rokach, Ariel
Amiad, Noa
Abdelrahman, Nader
Arish, Nissim
Chen-Shuali, Chen
Izbicki, Gabriel
Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels
title Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels
title_full Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels
title_fullStr Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels
title_full_unstemmed Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels
title_short Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels
title_sort prevalence and persistence of symptoms in adult covid-19 survivors 3 and 18 months after discharge from hospital or corona hotels
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784691/
https://www.ncbi.nlm.nih.gov/pubmed/36556030
http://dx.doi.org/10.3390/jcm11247413
work_keys_str_mv AT kalakgeorge prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels
AT jarjouiamir prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels
AT bohadanaabraham prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels
AT wildpascal prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels
AT rokachariel prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels
AT amiadnoa prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels
AT abdelrahmannader prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels
AT arishnissim prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels
AT chenshualichen prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels
AT izbickigabriel prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels